Why David Einhorn’s Greenlight prefers this tiny biotech over AI ‘excitement’

Greenlight Capital’s third-quarter investor letter had almost nothing good to say about the hot AI trend, but it does have faith in a tiny biotech.

Previous Article

Sweden Tells Citizens To Prepare For "War Mode"

Next Article

This one number explains the growing gulf between people who can afford to buy a house today — and those who can’t

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

− 4 = 1
Powered by MathCaptcha

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨